An Exploratory Study of the Effects of a Single Dose of QAX576 (an Interleukin-13 Monoclonal Antibody) on Simulated Hayfever

This study has been completed.
Information provided by:
Novartis Identifier:
First received: December 21, 2007
Last updated: September 1, 2010
Last verified: September 2010
This study will investigate whether a single dose QAX576 (an interleukin-13 monoclonal antibody) gives protection against a model of hayfever

Condition Intervention Phase
Allergic Rhinitis
Drug: QAX576
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Proof of Concept Study of the Effects of QAX576 (an Interleukin-13 Monoclonal Antibody) on Allergic Inflammation Following Out of Allergy Season Repeated Nasal Allergen Challenge in Subjects With Seasonal Allergic Rhinitis Sensitive to Timothy Grass Pollen

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Markers of allergic inflammation in the nose measured over 5-8 days post-dose. [ Time Frame: throughout the study ]

Secondary Outcome Measures:
  • - Nasal symptom scores over 5-8 days post-dose. - Blood levels of QAX576 to 3 months post-dose. - Marker of allergic inflammation in blood to 3 months post-dose. [ Time Frame: throughout the study ]

Enrollment: 36
Study Start Date: December 2007
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: QAX576
Placebo Comparator: 2 Drug: Placebo


Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • History of allergic rhinitis.

Exclusion Criteria:

  • Respiratory disease other than mild intermittent asthma.
  • Received immunotherapy in past 3 years.
  • History of clinically significant drug allergy.
  • History of clinical schistosomiasis or travel within 6 months prior to or following study to an area with endemic schistosomiasis.
  • History of exposure to human therapeutic antibodies, immunoglobulins or other plasma products.

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00584584

Novartis Investigator Site
Hannover, Germany
United Kingdom
Novartis Investigator Site
London, United Kingdom
Sponsors and Collaborators
Principal Investigator: NOVARTIS Novartis investigator site
  More Information

Responsible Party: External Affairs, Novartis Identifier: NCT00584584     History of Changes
Other Study ID Numbers: CQAX576A2104 
Study First Received: December 21, 2007
Last Updated: September 1, 2010
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Novartis:
Allergic rhinitis, adults, monoclonal antibody, interleukin-13.

Additional relevant MeSH terms:
Rhinitis, Allergic
Hypersensitivity, Immediate
Immune System Diseases
Nose Diseases
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Respiratory Tract Diseases
Respiratory Tract Infections
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs processed this record on May 26, 2016